Ginkgo Bioworks (DNA)

Search documents
Is Ginkgo Bioworks Stock a Buy Now?
The Motley Fool· 2024-02-24 13:30
Ginkgo Bioworks (DNA) has given investors a lot of hope that the business can generate significant growth in the future. But that hasn't panned out just yet. In the meantime, the company has been burning through cash and incurring huge losses.However, the cell programming company has been partnering with many top healthcare companies to help with drug discovery and biologic manufacturing, which should unlock growth opportunities down the road.Management recently provided investors with an encouraging update ...
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
The Motley Fool· 2024-02-23 07:59
Analysts on Wall Street have probably spent more time thinking about the price of stocks than you have, because it's their full-time job. That doesn't mean they're always correct, but it does suggest that there's a lot to learn from understanding their estimates and thinking about how they're made.On that note, per their consensus estimate, analysts are anticipating that two biotech stocks in particular could more than double their current value within the next 12 months. There's no guarantee it'll happen f ...
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation
Prnewswire· 2024-02-22 12:00
Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024 BOSTON, Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available ...
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
Prnewswire· 2024-02-15 12:02
BOSTON and LEXINGTON, Mass., Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc. (NYSE: DNA) and SaponiQx, I ...
House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025
Prnewswire· 2024-02-13 12:01
Members of Congress visited Ginkgo's Boston Seaport headquarters to discuss strategies for bolstering U.S. ability to compete in AI applications for biotechnology, as well as unlocking innovations in pharmaceuticals, agriculture, and across industries Ginkgo's Foundry generates essential data assets and tools to allow companies to more reliably develop biotech products Members also previewed Ginkgo's new Biofab1 facility, under construction in the Seaport, which is expected to significantly increase Ginkg ...
Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval
Prnewswire· 2024-02-01 12:00
KETCHUM, Idaho, Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States. With support from notable biotech leaders such as NFX and Ginkgo Bioworks (NYSE: DNA), Light Bio is reimagining the horticultural industry by introducing a new category of plants that emit an ethereal glow to enrich homes, gardens, and public spaces. Bioluminescent plants are now even brighter: Light ...
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
The Motley Fool· 2024-01-27 18:25
Growth stock investors have a lot to smile about these days. Optimism for stocks tied to innovative businesses is surging because the Federal Reserve is widely expected to cut interest rates this year.Lower costs of capital are a powerful tailwind for growth stocks. Shrinking interest rates make the future cash flows their underlying businesses could produce seem a lot more valuable in the present.Of course, not every growth stock is positioned to produce long-term gains for investors. However, the two I'm ...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week
The Motley Fool· 2024-01-25 16:55
There never seems to be a bad time for Cathie Wood to reshape her portfolios. The founder, CEO, and main stock-picker for the Ark Invest family of exchange-traded funds has been busy adding to some of her positions this week. She has also been pruning some of her holdings, but let's talk about the buys.Wood added to existing positions in Meta Platforms (META 0.74%), Recursion Pharmaceuticals (RXRX 0.96%), and Ginkgo Bioworks (DNA) this week. Let's take a closer look.1. Meta PlatformsOne of last year's bigge ...
Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
Prnewswire· 2024-01-15 12:00
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based ...
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
Prnewswire· 2024-01-10 12:35
Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business Strong growth among blue chip pharma and biotech ("biopharma") customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim Management to highlight updates today at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET) BOSTON, Jan. 10 ...